公开(公告)号：US20180116995A1

公开(公告)日：2018-05-03

申请号：US15852493

申请日：2017-12-22

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Tohru KAMBE ,  Toru MARUYAMA ,  Shinsaku YAMANE ,  Satoshi NAKAYAMA ,  Kousuke TANI

IPC分类号： A61K31/335 ,  A61K9/00 ,  C07D405/06 ,  C07D407/12 ,  A61K31/4427 ,  C07D401/06 ,  C07D313/06 ,  A61K31/558 ,  C07D417/04

CPC分类号： A61K31/335 ,  A61K9/0048 ,  A61K31/4427 ,  A61K31/558 ,  C07D313/06 ,  C07D401/06 ,  C07D405/06 ,  C07D407/12 ,  C07D417/04

摘要： Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.

公开(公告)号：US20220089532A1

公开(公告)日：2022-03-24

申请号：US17544616

申请日：2021-12-07

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Shoji NOJIMA ,  Kenji SASAKI ,  Tohru KAMBE ,  Takashi KONEMURA ,  Yoshikazu GOTO

IPC分类号： C07C311/21

摘要： A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).

公开(公告)号：US20190111019A1

公开(公告)日：2019-04-18

申请号：US16229446

申请日：2018-12-21

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Tohru KAMBE ,  Toru MARUYAMA ,  Shinsaku YAMANE ,  Satoshi NAKAYAMA ,  Kousuke TANI

IPC分类号： A61K31/335 ,  A61K9/00 ,  C07D405/06 ,  C07D407/12 ,  A61K31/4427 ,  C07D401/06 ,  C07D313/06 ,  A61K31/558 ,  C07D417/04

摘要： Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.

公开(公告)号：US20140073676A1

公开(公告)日：2014-03-13

申请号：US14081286

申请日：2013-11-15

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Tohru KAMBE ,  Toru MARUYAMA ,  Shinsaku YAMANE ,  Satoshi NAKAYAMA ,  Kousuke TANI

IPC分类号： C07D417/04 ,  C07D313/06 ,  C07D407/12

CPC分类号： A61K31/335 ,  A61K9/0048 ,  A61K31/4427 ,  A61K31/558 ,  C07D313/06 ,  C07D401/06 ,  C07D405/06 ,  C07D407/12 ,  C07D417/04

摘要： Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.

摘要翻译： 由于由通式（I）表示的化合物（其中每个基团的定义如说明书中所述），其盐，其溶剂化物或其前药具有强的和持续的眼内压降低活性，并且还具有 对眼睛没有副作用，如眼刺激性（充血，角膜混浊等），房水蛋白上升等，具有高度的安全性，可以作为预防和/或治疗青光眼等的优异剂。

公开(公告)号：US20200093781A1

公开(公告)日：2020-03-26

申请号：US16698432

申请日：2019-11-27

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Tohru KAMBE ,  Toru MARUYAMA ,  Shinsaku YAMANE ,  Satoshi NAKAYAMA ,  Kousuke TANI

IPC分类号： A61K31/335 ,  A61K31/4427 ,  A61K31/558 ,  C07D401/06 ,  C07D313/06 ,  C07D417/04 ,  C07D407/12 ,  C07D405/06 ,  A61K9/00

摘要： Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.

公开(公告)号：US20150112079A1

公开(公告)日：2015-04-23

申请号：US14587829

申请日：2014-12-31

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Tohru KAMBE ,  Toru MARUYAMA ,  Shinsaku YAMANE ,  Satoshi NAKAYAMA ,  Kousuke TANI

IPC分类号： C07D313/06 ,  C07D417/04 ,  C07D405/06

CPC分类号： A61K31/335 ,  A61K9/0048 ,  A61K31/4427 ,  A61K31/558 ,  C07D313/06 ,  C07D401/06 ,  C07D405/06 ,  C07D407/12 ,  C07D417/04

摘要： Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.

摘要翻译： 由于由通式（I）表示的化合物（其中每个基团的定义如说明书中所述），其盐，其溶剂化物或其前药具有强的和持续的眼内压降低活性，并且还具有 对眼睛没有副作用，如眼刺激性（充血，角膜混浊等），房水蛋白上升等，具有高度的安全性，可以作为预防和/或治疗青光眼等的优异剂。

公开(公告)号：US20210332009A1

公开(公告)日：2021-10-28

申请号：US17264603

申请日：2019-07-30

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Shoji NOJIMA ,  Kenji SASAKI ,  Tohru KAMBE ,  Takashi KONEMURA ,  Yoshikazu GOTO

IPC分类号： C07C311/21

摘要： A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).

公开(公告)号：US20210169842A1

公开(公告)日：2021-06-10

申请号：US17149327

申请日：2021-01-14

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Tohru KAMBE ,  Toru MARUYAMA ,  Shinsaku YAMANE ,  Satoshi NAKAYAMA ,  Kousuke TANI

IPC分类号： A61K31/335 ,  C07D313/06 ,  A61K31/4427 ,  C07D407/12 ,  A61K9/00 ,  C07D417/04 ,  C07D405/06 ,  A61K31/558 ,  C07D401/06

摘要： Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.

公开(公告)号：US20160287551A1

公开(公告)日：2016-10-06

申请号：US15180125

申请日：2016-06-13

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Tohru KAMBE ,  Toru MARUYAMA ,  Shinsaku YAMANE ,  Satoshi NAKAYAMA ,  Kousuke TANI

IPC分类号： A61K31/335 ,  A61K9/00

CPC分类号： A61K31/335 ,  A61K9/0048 ,  A61K31/4427 ,  A61K31/558 ,  C07D313/06 ,  C07D401/06 ,  C07D405/06 ,  C07D407/12 ,  C07D417/04

摘要： Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.